Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries.

Next Previous
Trial Profile

The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zotarolimus (Primary) ; Paclitaxel
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms RESOLUTE-Japan
  • Sponsors Medtronic

Most Recent Events

  • 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
  • 26 Jul 2011 1-Year results were presented at the 20th Annual Meeting of the Cardiovascular Intervention and Therapeutics (CVIT-2011).
  • 26 Jul 2011 Primary endpoint 'Late-loss' has been met (for noninferiority and superiority).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top